Program
THDB0206
A development code. Also written as “THDB0206 Injection”, “THDB0206 injection-Upper arm” and “THDB0206 Injection-Abdomen”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Tonghua Dongbao Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonghua Dongbao Pharmaceutical | 40 open or running | phase 3since Apr 17, 2023 | Apr 17, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2023First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT05834868 · 1,040 enrolled · China
- Nov 17, 2023Phase 1 study in HealthyNCT06153329 · 39 enrolled · China
- Nov 14, 2025Phase 1 study in Healthy ParticipantsNCT07257627 · 27 enrolled · China
- Dec 2, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT07282054 · 550 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07282054Diabetes Mellitus, Type 1 · China | 3 | Completed | Jan 23, 2025 | 550 |
| NCT07257627Healthy Participants · China | 1 | Completed | Dec 2, 2024 | 27 |
| NCT06153329Healthy · China | 1 | Completed | Jun 6, 2022 | 39 |
| NCT05834868Diabetes Mellitus, Type 2 · China | 3 | Completed | Dec 10, 2024 | 1,040 |
How it is read
Names in the registry
- “THDB0206 Injection”, 1 entry
- “THDB0206”, 1 entry
- “THDB0206 injection-Upper arm”, 1 entry
- “THDB0206 Injection-Abdomen”, 1 entry
- “THDB0206 Injection-Thigh”, 1 entry
Codes read as this program: THDB0206.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 1 study
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.